Reviews in Endocrine & Metabolic Disorders最新文献_第7页

The development of growth hormone-releasing hormone analogs: Therapeutic advances in cancer, regenerative medicine, and metabolic disorders. 生长激素释放激素类似物的开发：癌症、再生医学和代谢紊乱的治疗进展。

IF 6.9 2区医学

Reviews in Endocrine & Metabolic Disorders Pub Date : 2025-06-01 Epub Date: 2024-11-26 DOI: 10.1007/s11154-024-09929-2

Andrew V Schally, Renzhi Cai, Xianyang Zhang, Wei Sha, Medhi Wangpaichitr

{"title":"The development of growth hormone-releasing hormone analogs: Therapeutic advances in cancer, regenerative medicine, and metabolic disorders.","authors":"Andrew V Schally, Renzhi Cai, Xianyang Zhang, Wei Sha, Medhi Wangpaichitr","doi":"10.1007/s11154-024-09929-2","DOIUrl":"10.1007/s11154-024-09929-2","url":null,"abstract":"Growth Hormone-Releasing Hormone (GHRH) and its analogs have gained significant attention for their therapeutic potential across various domains, including oncology, regenerative medicine, and metabolic disorders. Originally recognized for its role in regulating growth hormone (GH) secretion, GHRH has since been discovered to exert broader physiological effects beyond the pituitary gland, with GHRH receptors identified in multiple extrahypothalamic tissues, including tumor cells. This review explores the development of both GHRH agonists and antagonists, focusing on their mechanisms of action, therapeutic applications, and future potential. GHRH agonists have shown promise in promoting tissue regeneration, improving cardiac function, and enhancing islet survival in diabetes. Meanwhile, GHRH antagonists, particularly those in the MIA and AVR series, demonstrate potent antitumor activity by inhibiting cancer cell proliferation and downregulating growth factor pathways, while also exhibiting anti-inflammatory properties. Preclinical studies in models of lung, prostate, breast, and gastrointestinal cancers indicate that GHRH analogs could offer a novel therapeutic approach with minimal toxicity. Additionally, GHRH antagonists are being investigated for their potential in treating neurodegenerative diseases and inflammatory conditions. This review highlights the versatility of GHRH analogs as a promising class of therapeutic agents, poised to impact multiple fields of medicine.","PeriodicalId":21106,"journal":{"name":"Reviews in Endocrine & Metabolic Disorders","volume":" ","pages":"385-396"},"PeriodicalIF":6.9,"publicationDate":"2025-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12137413/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142732054","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Effects of GHRH and its analogues on the Vascular System. GHRH 及其类似物对血管系统的影响。

IF 6.9 2区医学

Reviews in Endocrine & Metabolic Disorders Pub Date : 2025-06-01 Epub Date: 2024-11-21 DOI: 10.1007/s11154-024-09932-7

Hong Yu, Huan Peng

引用次数: 0

Growth hormone-releasing hormone receptor (GHRH-R) and its signaling. 生长激素释放激素受体（GHRH-R）及其信号传导。

IF 6.9 2区医学

Reviews in Endocrine & Metabolic Disorders Pub Date : 2025-06-01 Epub Date: 2025-02-12 DOI: 10.1007/s11154-025-09952-x

Gabor Halmos, Zsuzsanna Szabo, Nikoletta Dobos, Eva Juhasz, Andrew V Schally

{"title":"Growth hormone-releasing hormone receptor (GHRH-R) and its signaling.","authors":"Gabor Halmos, Zsuzsanna Szabo, Nikoletta Dobos, Eva Juhasz, Andrew V Schally","doi":"10.1007/s11154-025-09952-x","DOIUrl":"10.1007/s11154-025-09952-x","url":null,"abstract":"The hypothalamic polypeptide growth hormone-releasing hormone (GHRH) stimulates the secretion of growth hormone (GH) from the pituitary through binding and activation of the pituitary type of GHRH receptor (GHRH-R), which belongs to the family of G protein-coupled receptors with seven potential membrane-spanning domains. Various splice variants of GHRH-R (SV) in human neoplasms and other extrapituitary tissues were demonstrated and their cDNA was sequenced. Among the SVs, splice variant 1 (SV1) possesses the greatest similarity to the full-length GHRH-R and remains functional by eliciting cAMP signaling and mitogenic activity upon stimulation by GHRH. In this review, we briefly discuss the activation, regulation, molecular mechanisms and signaling pathways of GHRH-Rs and their SVs in various tissues and also summarize the expression, biological activities and potential function of GHRH, its analogs and their receptors. A large body of work have extensively studied and evaluated potential clinical applications of agonists and antagonists of GHRH in diverse fields, including oncology, endocrinology, obesity, diabetes, other metabolic dysfunctions, cardiology, immune functions, mood disorders, Alzheimer's and lung disease, ophthalmology, inflammation, wound healing and other applications. These results strongly support the potential therapeutic use of GHRH analogs in human medicine in the near future.","PeriodicalId":21106,"journal":{"name":"Reviews in Endocrine & Metabolic Disorders","volume":" ","pages":"343-352"},"PeriodicalIF":6.9,"publicationDate":"2025-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12137518/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143399843","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Hypothalamic control of heart rate and body temperature by thyroid hormones. 下丘脑通过甲状腺激素控制心率和体温。

IF 6.9 2区医学

Reviews in Endocrine & Metabolic Disorders Pub Date : 2025-04-17 DOI: 10.1007/s11154-025-09966-5

Jens Mittag, Beke Kolms

引用次数: 0

Complexity in the interpretation and application of multiple guidelines for thyroid nodules: the need for coordinated recommendations for "small" lesions. 多种甲状腺结节指南解释和应用的复杂性：“小”病变需要协调一致的建议。

IF 6.9 2区医学

Reviews in Endocrine & Metabolic Disorders Pub Date : 2025-04-01 Epub Date: 2025-02-04 DOI: 10.1007/s11154-025-09950-z

Pierpaolo Trimboli

{"title":"Complexity in the interpretation and application of multiple guidelines for thyroid nodules: the need for coordinated recommendations for \"small\" lesions.","authors":"Pierpaolo Trimboli","doi":"10.1007/s11154-025-09950-z","DOIUrl":"10.1007/s11154-025-09950-z","url":null,"abstract":"Multiple guidelines for thyroid nodule management have been developed by endocrinologists, often in collaboration with surgeons and radiologists. While there is now a lot of scientific information available to meet the needs of healthcare providers, there is not always uniformity and standardization among recommendations. Consequently, the interpretation and application of guidelines in clinical practice remain somewhat limited. In this context, the management of \"small\" thyroid nodule warrants full discussion. Looking at treatment guidelines, surgery is the first-line option and the risk of cancer relapse can be assessed only after at least thyroidectomy; in addition, according to guidelines of minimally invasive treatment, thermal ablation may be considered for patients with small classical papillary carcinoma. However, the Thyroid Imaging Reporting And Data Systems do not recommend biopsy in nodules less than 1 cm; and performing biopsy may yield a result that is suspicious or consistent with malignancy without specifying the cancer subtype. With these premises, facing cases of \"small\" nodule less than 1 cm is challenging. Even if the recommendations of guidelines sound singularly appropriate, they may seem conflicting. Coordinated guidelines are needed.","PeriodicalId":21106,"journal":{"name":"Reviews in Endocrine & Metabolic Disorders","volume":" ","pages":"223-227"},"PeriodicalIF":6.9,"publicationDate":"2025-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11919924/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143190347","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Melatonin administration on bone properties of animals under hypoestrogenism: A systematic review. 褪黑素对低雌激素动物骨特性的影响：系统综述。

IF 8 2区医学

Reviews in Endocrine & Metabolic Disorders Pub Date : 2025-04-01 Epub Date: 2025-02-26 DOI: 10.1007/s11154-025-09953-w

Taciane Maria Melges Pejon, Leonardo Henrique Dalcheco Messias, Rafael Henrique de Oliveira Nascimento, Vanessa Bertolucci, André Felipe Ninomiya, Wladimir Rafael Beck

{"title":"Melatonin administration on bone properties of animals under hypoestrogenism: A systematic review.","authors":"Taciane Maria Melges Pejon, Leonardo Henrique Dalcheco Messias, Rafael Henrique de Oliveira Nascimento, Vanessa Bertolucci, André Felipe Ninomiya, Wladimir Rafael Beck","doi":"10.1007/s11154-025-09953-w","DOIUrl":"10.1007/s11154-025-09953-w","url":null,"abstract":"Purpose: Hypoestrogenism is associated with loss of bone mass and strength. Melatonin has become a strategy due to its actions on bone tissue. This review summarizes the available data on the effects of chronic melatonin administration on bone tissue in animal models with hypoestrogenism.Data sources: A systematic search of the PubMed, Web of Science, and Scopus, databases up to November 27, 2023, was conducted using specified key terms and Boolean operators (bone AND bones OR bone density OR bone diseases OR osteogenesis OR osteoporosis AND melatonin).Study selection: only controlled studies in English and with rodents.Study design: systematic review.Data extraction: animals' characteristics (sex and hypoestrogenism confirmation), dose, route, and duration of administration of melatonin, and outcomes from the properties of bone.Results: A total of 25 studies were identified after the screening process. In the hypoestrogenic state, melatonin administration improved bone mineral density, bone volume ratio, trabecular number in 19 studies, and maximal load/strength and stiffness test in 7. 4 studies reported improved matrix mineralization in bone marrow mesenchymal stem cells. Melatonin increased the expression of RUNX2 in 9 studies, OCN in 6, and OPG in 4, while decreasing RANKL in 3. In 4 studies the melatonin increased the serum osteocalcin levels.Conclusion: Chronic administration of melatonin appears to improve the biophysical, biomechanical, molecular, and biochemical properties of bone tissue. These benefits promote an osteogenic effect, making melatonin an efficient strategy to preserve microarchitecture and tissue mass in a state of hypoestrogenism.","PeriodicalId":21106,"journal":{"name":"Reviews in Endocrine & Metabolic Disorders","volume":" ","pages":"279-291"},"PeriodicalIF":8.0,"publicationDate":"2025-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143503543","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

The radiologic spectrum of neuroendocrine tumors in emergent care. 急诊神经内分泌肿瘤的放射谱分析。

IF 6.9 2区医学

Reviews in Endocrine & Metabolic Disorders Pub Date : 2025-04-01 Epub Date: 2025-01-02 DOI: 10.1007/s11154-024-09940-7

Asutosh Sahu, Michael Patlas, Ankush Jajodia

引用次数: 0

Pituitary adenomas: biology, nomenclature and clinical classification. 垂体腺瘤：生物学、命名和临床分类。

IF 6.9 2区医学

Reviews in Endocrine & Metabolic Disorders Pub Date : 2025-04-01 Epub Date: 2025-01-25 DOI: 10.1007/s11154-025-09944-x

Ken K Y Ho, Shlomo Melmed

{"title":"Pituitary adenomas: biology, nomenclature and clinical classification.","authors":"Ken K Y Ho, Shlomo Melmed","doi":"10.1007/s11154-025-09944-x","DOIUrl":"10.1007/s11154-025-09944-x","url":null,"abstract":"An 'adenoma' is a benign neoplasm composed of epithelial tissue, and has been standard nomenclature for primary pituitary neoplasms. In 2022, the fifth edition of the WHO Classification of Endocrine Tumours and of Central Nervous System Tumours, renamed pituitary adenomas as neuroendocrine tumours (NETs), assigning an oncology label to pituitary invariably benign neoplasms. Multidisciplinary workshops convened by the Pituitary Society have questioned the process, validity, and merit of this arbitrary change, while addressing the adverse clinical implications of the proposed new nomenclature. Unlike NETs, pituitary adenomas are highly prevalent, indolent and very rarely become malignant, and in general do not affect life expectancy when appropriately managed. A nomenclature change to NET does not advance mechanistic insight, treatment or prognosis but confers a misleading oncology connotation, potentially leading to overtreatment as well as engendering unnecessary patient anxiety. As the majority of pituitary adenomas do not require surgery, exclusion of these disorders is a major shortcoming of the pathology-based WHO classification system which is limited to patients undergoing surgery. Many factors influence prognosis other than histopathology. A new clinical classical classification has been developed for guiding prognosis and therapy of pituitary adenomas by integrating clinical, genetic, biochemical, radiological, pathological, and molecular information for all adenomas arising from anterior pituitary cell lineages. The system uses an evidence-based scoring of risk factors to yield a cumulative grade score that reflects disease severity. It can be used at the bedside to guide pituitary adenoma management. Once validated in prospective studies, this simple classification system could provide a standardised platform for assessing disease severity, prognosis, and effects of therapy on pituitary adenoma outcomes.","PeriodicalId":21106,"journal":{"name":"Reviews in Endocrine & Metabolic Disorders","volume":" ","pages":"137-146"},"PeriodicalIF":6.9,"publicationDate":"2025-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143041071","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

From pituitary cells to prostate gland in health and disease: direct and indirect endocrine connections. 从健康和疾病中的垂体细胞到前列腺：直接和间接的内分泌联系。

IF 6.9 2区医学

Reviews in Endocrine & Metabolic Disorders Pub Date : 2025-04-01 Epub Date: 2025-02-06 DOI: 10.1007/s11154-025-09948-7

André Sarmento-Cabral, Antonio C Fuentes-Fayos, Fernando Mata Ordoñez, Antonio J León-González, Antonio J Martínez-Fuentes, Manuel D Gahete, Raúl M Luque

{"title":"From pituitary cells to prostate gland in health and disease: direct and indirect endocrine connections.","authors":"André Sarmento-Cabral, Antonio C Fuentes-Fayos, Fernando Mata Ordoñez, Antonio J León-González, Antonio J Martínez-Fuentes, Manuel D Gahete, Raúl M Luque","doi":"10.1007/s11154-025-09948-7","DOIUrl":"10.1007/s11154-025-09948-7","url":null,"abstract":"The prostate gland is an endocrine-sensitive organ responding to multiple stimuli. Its development and function are regulated by multiple hormones (i.e. steroids such as androgens, estrogens and glucocorticoids) but also by other key hormonal systems such as those comprised by insulin-like growth factor 1 and insulin, which are sourced by different tissues [e.g. testicles/adrenal-gland/adipose-tissue/liver/pancreas, etc.). Particularly important for the endocrine control of prostatic pathophysiology and anatomy are hormones produced and/or secreted by different cell types of the pituitary gland [growth-hormone, luteinizing-hormone, follicle-stimulating hormone, and prolactin, oxytocin, arginine-vasopressin and melanocyte-stimulating hormone], which affect prostate gland function either directly or indirectly under physiological and pathophysiological conditions [e.g. metabolic dysregulation (e.g. obesity), and prostate transformations (e.g. prostate cancer)]. This review summarizes the impact of all pituitary hormone types on prostate gland under these diverse conditions including in vivo and in vitro studies.","PeriodicalId":21106,"journal":{"name":"Reviews in Endocrine & Metabolic Disorders","volume":" ","pages":"187-203"},"PeriodicalIF":6.9,"publicationDate":"2025-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11920336/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143256568","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Rathke's cleft cyst: From history to molecular genetics. 拉特克裂隙囊肿：从历史到分子遗传学。

IF 6.9 2区医学

Reviews in Endocrine & Metabolic Disorders Pub Date : 2025-04-01 Epub Date: 2025-02-13 DOI: 10.1007/s11154-025-09949-6

Aysa Hacioglu, Halil Tekiner, Meric A Altinoz, Gazanfer Ekinci, Jean-François Bonneville, Kaan Yaltirik, Aydin Sav, Ugur Ture, Fahrettin Kelestimur

{"title":"Rathke's cleft cyst: From history to molecular genetics.","authors":"Aysa Hacioglu, Halil Tekiner, Meric A Altinoz, Gazanfer Ekinci, Jean-François Bonneville, Kaan Yaltirik, Aydin Sav, Ugur Ture, Fahrettin Kelestimur","doi":"10.1007/s11154-025-09949-6","DOIUrl":"10.1007/s11154-025-09949-6","url":null,"abstract":"A Rathke's cleft cyst (RCC) is a remnant of the embryologic Rathke's pouch and a common pituitary lesion. A true RCC is lined with ciliated cuboidal or columnar epithelia with occasional goblet cells and squamous metaplasia. A RCC is frequently diagnosed incidentally through magnetic resonance imaging and computed tomography of the brain or pituitary gland. Presentation can range from an asymptomatic clinical picture to a rapidly progressive disease. RCC are located most often in the sellar and suprasellar regions and a careful differential diagnosis is crucial, especially to exclude craniophryngioma. Recent studies illuminate novel molecular mechanisms and markers for understanding the pathogenesis of RCC. PROP-1, a paired-like homeodomain transcription factor, controls pituitary ontogeny and its high expression induces RCCs. Both transgenic mouse models and immunohistochemical analysis of human RCCs indicate that the leukemia inhibitory factor is involved in pathogenesis. The expression of cytokeratins 8 and 2 in RCCs, but not in craniopharyngiomas, and the presence of beta-catenin mutations in many craniopharyngiomas, but not in RCCs, help with the differential diagnosis. For asymptomatic and small RCCs, observation is appropriate, with serial magnetic resonance imaging and hormonal investigation depending on the patient's clinical status. Surgical resection may be required for symptomatic RCC and recurrence rates are generally low. For patients with a recurrence, stereotactic radiosurgery is an effective approach with low risk.","PeriodicalId":21106,"journal":{"name":"Reviews in Endocrine & Metabolic Disorders","volume":" ","pages":"229-260"},"PeriodicalIF":6.9,"publicationDate":"2025-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11920404/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143410333","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0